Catalyst Wire Dossier Catalyst Wire Dossier

AG regimen (Adriamycin/doxorubicin + gemcitabine)

doxorubicin + gemcitabine
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AG regimen (Adriamycin/doxorubicin + gemcitabine), covering 2025-11-17 to 2025-11-17. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Study Evaluating the Safety, Tolerability, Preliminary Efficacy and Immunogenicity of a Tumor Vaccine Injection Targeting Stressinducible Proteins MICA/B in Combination With the AG Regimen in Patients With Metastatic Pancreatic Cancer [EARLY_Phase 1]

See pricing